NanoCelle® – a gamechanger for human health and beyond

The application of nanotechnology in medicine offers exciting possibilities to improve and discover new drug delivery systems, therapies, diagnostics, anti-microbial techniques, and forms of cell repair. In fact, researchers keep reengineering nanoparticles to treat drug-resistant cancers. 
Medlab's NanoCelle® drug delivery platform has been created to administer medicines directly into the bloodstream, without needles or pills. NanoCelle® formulation that utilises submicron particles to elaborate a standardised medicine.
Our research into nano-sized particles has spanned more than two decades and our patented technology is a gamechanger for enhancing medicines and more.

Medlab's sub-micron particle NanoCelle® demonstrates:

3D Image of a Medlab NanoCelle® Medicine under trial

•Enhanced bioavailability

•Micelle micro-emulsion 

•Clear, stable, water-soluble formulations

•Stability up to two years at room temperature

•Scalable - 50 mL to 1000 liters

•Dosing Flexibility: oro-buccal sprays, nasal sprays, oral gels, dermal and transdermal formulations, topical gels, topical lotions, ingestible liquids, adsorption onto solid carriers

•Applications: a wide variety of hydrophobic drugs, nutrients, oil extracts, and peptides

Other applications of NanoCelle®

  • Generics and small molecules

Shown to lower dosage and reduce side effects in generic pharmaceuticals including statins, steroids, ACEi's, and antibiotics. To learn more about NanoCelle® delivery in small molecules click HERE

  • Biologics, vaccines, and large molecules

Shown to provide a needle-free alternative to traditional vaccine delivery. To learn more about NanoCelle® delivery in large molecules and its new hydrogel innovation click HERE

  • Smart Wearables

Opportunity to develop triggered release of medication within medical-related garments and "smart wearables". To learn more about NanoCelle® textiles click HERE


How does NanoCelle® work?

NanoCelle® creates nano-sized water-soluble particles that carry medicine or active ingredient with 95% bioavailability, meaning they can pass directly into the bloodstream for faster absorption and metabolism.

Traditional oral drug delivery relies on the active ingredient being absorbed through the gastrointestinal tract and metabolized by the liver before reaching the bloodstream. NanoCelle® allows for the active ingredient to bypass the gut and instead enhances oral-buccal, intranasal, and topical or transdermal delivery directly into the bloodstream.

The most common use of NanoCelle® is to spray the inside of the cheek to reach the bloodstream via the oral-buccal membrane.

Regardless of the original solubility characteristics of the active ingredient, NanoCelle® creates water-soluble particles that are less than 100 nanometres in size with a hydrophobic core and hydrophilic shell.

NanoCelle® technology can be utilised in multiple drug delivery systems from oral-buccal, intranasal, and topical or

transdermal delivery directly into the bloodstream.

Enhancing solubility to improve absorption

The bioavailability (the percentage of active ingredient absorbed into the bloodstream) of orally administered drugs are strongly influenced by their solubility and permeability across the GIT mucosal epithelium. 

However, NanoCelle® creates water-soluble nano-sized particles that can pass directly across the oral-buccal membrane, improving the absorption and efficacy of medicines.

NanoCelle® applications currently in development

NanoCelle® has been applied to a wide range of ingredients including ascorbate, CoQ10, curcumin, insulin, steroids, ACE inhibitors, antibiotics and immunosuppressive agents. 


Particle Size (nm)



Ampicillin Sodium Salt (2162016AMP)- antibiotics


2 mg/mL

0.6 mg/0.3mL

Atorvastatin (1022015ATO)


10 mg/mL

3 mg/0.3mL

Atorvastatin (1232015ATO)


0.1 mg/mL

0.03 mg/0.3mL

Atorvastatin (03212017ATO)


8.3 mg/mL

2.49 mg/0.3mL

Atorvastatin (3152017ATO)


13.3 mg/mL

3.99 mg/0.3mL

Atorvastatin-25 (12142015ATO25)


1.67 mg/mL

0.5 mg/0.3mL

Atorvastatin-30 (12142015ATO30)


1.67 mg/mL

0.5 mg/0.3mL

Atorvastatin (2162016ATO)


10 mg/mL

3 mg/0.3mL

Beta-Estradiol (2162016EST)-hormones


1 mg/mL

0.3 mg/0.3mL

Fexofenadine (TelfastTM)


4 mg/mL

1.2 mg/0.3mL

Dexamethasone (2162016DEX)-hormones


2.6 mg/mL

0.78 mg/0.3mL

Insulin (1022015INS)


15 IU/mL

4.5 mg/0.3mL

Perindopril Erbumine (2162016PER)-ACEi


7 mg/mL

2.1 mg/0.3mL

Progestogen (2162016PEO)-hormones


2 mg/mL

0.6 mg/0.3mL

Rosuvastatin (1022015ROS)-statin


2 mg/mL

0.6 mg/0.3mL

Rosuvastatin (1022015ROS)-statin


2 mg/mL

0.6 mg/0.3mL

Sertraline Hydrochloride (2162016SER)-SSRI


0.5 mg/mL

0.15 mg/0.3mL

Testosterone Propionate (123015TES)-hormones


15 mg/mL

4.5 mg/0.3mL

CoQ10 (2182916CoQ10)


100 mg/mL

30 mg/0.3mL

CoQ10 (2182916CoQ10)


100 mg/mL

30 mg/0.3mL



3333 IU/ mL

1000 IU/0.3 mL

D3 & K2 (2182016D3K2)


3333 IU+150mcg/0.3 mL

1000 IU+45 mcg/0.3 mL

Melatonin (2182016MEL)


8.3 mg/mL


Cyanocobalamin B12


3333 IU/ mL

1000 IU/0.3 mL

Methylcobalamin B12 (2182016B12)


3333 IU/ mL

1000 IU/0.3 mL

NanaBidialTM (<1:20 THC:CBD (20mg/mL CBD and less than 1mg/mL THC)

20.13 nm

8.3 mg/mL


NanaBisTM (1:1 THC:CBD (8.33mg/mL THC and 8.33mg/mL CBD)

33.33 nm

8.3 mg/mL


NanoCBD™(16.66 mg/mL CBD)

21.29 nm

16.67 mg/mL


NanoCelle® third party validation

Medlab partners with Particle Technology Labs Ltd (PTL) 

PTL is a premier particle technology research company and trusted advisor to the world's industry leaders in pharmaceuticals, manufacturing, defence, agriculture, food and beverage industry as well as the public sector and scientific organisations. 

PTLs’ expert analysts generate unbiased particle characterization research information and regulatory compliance. 

How will Nanotechnology progress medicine?

Nanotechnology can enhance medical delivery and therefore the efficacy of pharmaceutical, nutraceutical, and herbal medicines.

In multiple studies, NanoCelle® has demonstrated efficacy at a fraction of the dose of its tablet or liquid counterparts. This means patients don’t need to take as much medicine and are at lower risk of side effects or drug-on-drug interactions.

NanoCelle® has been used in over 100,000 units dispensed to patients and offers exciting possibilities from its application to drug delivery, therapy techniques, and diagnostic techniques.

Simple, viable, scalable production


  • Medlab’s NanoCelle® production process has obvious advantages – using readily available materials with low economic costs
  • Simple processing method that can be easily done in single-day production, using standard pharmaceutical liquid manufacturing equipment
  • Able to be scaled up for high-volume production
  • Replicable procedure that, with minor adjustments, can be applied to a wide variety of active ingredients, both nutritional and pharmaceutical
  • Technology transfer expectations are estimated at three months, based on the recipient having heated jacket capabilities
  • API validated by the University of Sydney and Particle Technology Labs, USA

Product Development

Medlab continues to formulate and refine better solutions using nanotechnology.

Are you looking to deliver more?


Get in touch to discuss how NanoCelle® could innovate your future developments.

Partner with us